iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
April 15, 2020, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo"
iCo Therapeutics Announces Leadership Changes
March 09, 2020, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo"
iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B
February 25, 2020, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo"
iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing & Follow Up
February 10, 2020, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo"
iCo Therapeutics Announces Option Grants
January 10, 2020, Vancouver, Canada — iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or
iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
December 24, 2019, Vancouver, Canada — iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the
iCo Therapeutics Engages Ora for iCo-008 Ophthalmic Strategy and Pre Phase II FDA Meeting
December 11, 2019, Vancouver, Canada — iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo"
iCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)
February 19, 2019, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V: